Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Metastasis02:30

Metastasis

5.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ENPP3 CAR T cells combined with CD206 modulation suppress adrenocortical carcinoma.

Journal for immunotherapy of cancer·2026
Same author

ATF2 phosphorylation is a core transcriptional driver of neuron apoptosis.

Neuron·2026
Same author

Pilot study evaluating tolerability and changes in fecal microbiota associated with novel probiotic administration to dogs with diarrhea.

Frontiers in veterinary science·2026
Same author

Low prevalence of hemoperitoneum recurrence in dogs following splenectomy for benign splenic tumors.

Frontiers in veterinary science·2025
Same author

The Kinase Inhibitor GNF-7 Is Synthetically Lethal in Topoisomerase 1-Deficient Ewing Sarcoma.

Cancers·2025
Same author

Intravenous allogeneic mesenchymal stromal cell therapy in 13 Pugs with presumptive early necrotizing meningoencephalitis.

Journal of the American Veterinary Medical Association·2025

Related Experiment Video

Updated: May 5, 2026

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

7.8K

Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells.

Lara H El Touny, Anthony Vieira, Arnulfo Mendoza

    The Journal of Clinical Investigation
    |December 10, 2013
    PubMed
    Summary
    This summary is machine-generated.

    Targeting Src family kinases (SFK) prevents dormant breast cancer (BC) cell proliferation. Combining SFK and MEK1/2 inhibitors induces apoptosis, potentially preventing BC recurrence.

    More Related Videos

    An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth
    09:14

    An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth

    Published on: August 11, 2011

    15.1K
    Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
    13:38

    Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

    Published on: January 18, 2017

    9.7K

    Related Experiment Videos

    Last Updated: May 5, 2026

    An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
    08:48

    An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

    Published on: June 30, 2015

    7.8K
    An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth
    09:14

    An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth

    Published on: August 11, 2011

    15.1K
    Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
    13:38

    Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

    Published on: January 18, 2017

    9.7K

    Area of Science:

    • Oncology
    • Molecular Biology
    • Cancer Research

    Background:

    • Breast cancer (BC) recurrence can arise from dormant disseminated tumor cells years after treatment.
    • Tumor microenvironment alterations, like fibrosis, can reactivate dormant BC cells.
    • The mechanisms regulating the switch from dormancy to proliferation are not fully understood.

    Purpose of the Study:

    • To investigate the role of Src family kinases (SFK) in the dormant-to-proliferative switch of BC cells.
    • To evaluate the therapeutic potential of targeting SFK and MEK1/2 pathways in dormant BC.

    Main Methods:

    • Utilized in vivo preclinical and 3D in vitro models of BC dormancy.
    • Assessed the effect of SFK inhibition (pharmacological and genetic) on dormant cell proliferation.
    • Investigated the role of ERK1/2 activation in dormant cell proliferation.
    • Evaluated combination therapy with SFK and MEK1/2 inhibitors.

    Main Results:

    • SFK inhibition prevented dormant BC cell proliferation and metastatic lesion formation by promoting p27 nuclear localization.
    • SFK inhibition alone did not eliminate dormant cells.
    • Dormant cell proliferation required ERK1/2 activation.
    • Combination therapy with SFK (AZD0530) and MEK1/2 (AZD6244) inhibitors induced apoptosis and delayed metastatic outgrowth.

    Conclusions:

    • Targeting SFK can block the proliferative response of dormant BC cells to external stimuli.
    • Combined inhibition of SFK and MEK1/2 is necessary to induce apoptosis and suppress the survival of reactivated dormant BC cells.
    • This combination therapy strategy shows promise for preventing BC recurrence.